Introduction {#S1}
============

Genome-wide association studies (GWAS) have recently identified a large number of genome-wide significant loci with an impact on body mass index (BMI; kg/m^2^)/obesity, body composition, and body fat distribution on the one hand, and independently on mental disorders and quantitative mental traits on the other hand. The most recent GWAS for anthropometric traits were all published in 2019 substantiating the rapidly evolving dissection of their polygenic basis: (a) for BMI, 941 near-independent genome-wide significant SNPs at 536 polygenic loci have been detected ([@B146]). (b) A GWAS for whole-body lean body mass (LBM; adjusted for sex, age, and height with or without fat mass adjustments) revealed seven LBM loci ([@B51]). Another very recent GWAS for the proportion of body fat distribution in arms, legs, and trunk on 362,499 individuals from the UK Biobank identified 98 independent loci, 29 of which had not previously been associated with anthropometric traits including BMI ([@B110]). (c) The most recent GWAS for body fat distribution as measured by waist-to-hip ratio adjusted for BMI (WHR~adjBMI~) reported 463 independent signals (*P* \< 5 × 10^--9^) in 346 loci ([@B107]). Because BMI and waist circumference (WC), hip circumference (HC), and WHR are more or less strongly correlated in adults (correlation coefficients of approximately 0.8 for BMI,WC, and HC, respectively; 0.3 for BMI and WHR; see e.g., [@B118]), WC, HC, and WHR have been analyzed as such in GWAS ([@B45]; [@B140]; [@B122]), but have also been adjusted for BMI ([@B122]; [@B39]; [@B107]).

Substantial progress has also been achieved toward the elucidation of the polygenic basis of several mental disorders \[schizophrenia ([@B115]), autism (ASD; [@B40]), major depressive disorder (MDD; [@B143]), bipolar disorder (BD; [@B127]), attention deficit/hyperactivity disorder (ADHD; [@B67]; [@B28]), anxiety disorders ([@B98]), and anorexia nervosa (AN; [@B32])\] and quantitative mental traits \[intelligence ([@B124]; [@B47]), educational attainment ([@B97]; [@B62]), tiredness ([@B26]), openness ([@B25]), conscientiousness ([@B25]; [@B71]), neuroticism ([@B96]; [@B71]; [@B76]), well-being ([@B96]), and depressive symptoms ([@B96])\]. The highest number of genome-wide significant loci (*n* = 1,271) has been detected for educational attainment ([@B62]). With respect to mental disorders, the most loci (*n* = 145; [@B99]) have been identified for schizophrenia, for other disorders only one genome-wide significant hit \[e.g., anxiety disorders ([@B98]), AN ([@B32]), conscientiousness ([@B25]), and tiredness ([@B26])\] has been described.

To address the association of obesity with mental disorders, both clinical and population-based studies have been conducted cross-sectionally and longitudinally ([@B112]; [@B100]). Particularly well analyzed are associations between obesity and depression ([@B78]; [@B9]; [@B87]; [@B84]) and ADHD ([@B20]; [@B92]), respectively. For obesity and MDD, a bidirectional, partly sex dependent relationship applies, entailing that obesity can precede MDD and vice versa ([@B77]; [@B87]; [@B21]). An association with obesity was also reported for BD and schizophrenia ([@B42]). Because of the adverse effect of weight gain inherent to several psychotropic drugs, especially atypical antipsychotics ([@B3]), a reliable assessment of the respective associations can only be based on drug-naïve or previously untreated patients ([@B42]). A meta-analysis for BMI and WHR in never or minimally treated patients with psychosis or schizophrenia found lower BMI and elevated WHR in patients compared to healthy controls. No differences in WC were observed ([@B120]).

Observed clinical relationships between anthropometric traits BMI, obesity, body composition, and fat distribution have partially been supported by the detection of significant genetic correlations; in addition, genetic correlations have gone beyond established clinical associations. Significant negative genetic correlations have been described for BMI (or obesity) with educational attainment, intelligence, and neuroticism as well as with schizophrenia and BD. Positive genetic correlations have been found between BMI (or obesity) and ADHD and depression ([@B15]; [@B150]; [@B47]; [@B114])^[1](#footnote1){ref-type="fn"}^: (a) The negative genetic correlations between body fat percentage (BF%) and educational attainment and schizophrenia should also be highlighted ([@B114])^[1](#footnote1){ref-type="fn"}^; (b) At the functional level, several genes coding for proteins involved in synaptic function have been associated with substance use, obesity-related traits, responses to mental and physical stress, heart rate, and blood pressure measurements ([@B93]).

Thus, complex anthropometric and mental phenotypes may reveal extensive overlapping genetic factors. Research is clearly warranted to identify genetic variation involved both in the (1) regulation of body weight, body composition, and body fat distribution and (2) in mental disorders/traits. Particularly, body fat distribution is of great importance, because visceral fat (abdominal obesity) is the main factor underlying the clinical association between obesity and hypertension and type 2 diabetes mellitus ([@B125]). Because stress is presumed to play an important role in the development of abdominal obesity ([@B11]; [@B36]; [@B132]), as well as in the pathogenesis of mental disorders ([@B19]), a genetic link especially with body fat distribution may be particularly pronounced.

The purpose of the current study was to perform for the first time a systematic look-up analysis to assess the potential overlap of genome-wide significant loci for a range of anthropometric traits with mental disorders/traits. Methodologically similar to our previous study, which assessed the role of metabolite SNPs in mental disorders/traits ([@B46]), we initially identified all genome-wide significant SNPs for the anthropometric traits. Look-ups were subsequently performed in GWAS data sets for 15 mental disorders/traits. For our initial look-up analysis we used data from the GWAS catalog in December 2017. We aimed for more detailed analyses in follow-up studies. Thus, to keep up with the rapid pace in the GWAS field, we have used the latest data set for each phenotype for our *post hoc* analyses \[effect sizes and directions, Mendelian randomization; e.g., for BMI ([@B146]), body fat distribution ([@B107]) or schizophrenia ([@B99]), and MDD ([@B143])\].

The term "mental disorders" refers to disorders delineated in DSM-5 ([@B4]). Mental traits refer to quantitative personality/character, behavioral and socio-psychological traits. We use the overarching term mental phenotypes to refer to both mental disorders and mental traits. Apart from the genetic contribution, there are strong environmental, behavioral, and social components to some of these phenotypes ([@B83]).

To exemplarily investigate the potential causality of SNPs for body fat distribution in schizophrenia (and vice versa) in *post hoc* analyses, we performed a two-sample Mendelian randomization (MR) analysis with WHR~adjBMI~ as exposure and the risk for schizophrenia as outcome. In the reverse MR we used the risk of schizophrenia ([@B113]) as exposure and WHR~adjBMI~ as outcome.

Materials and Methods {#S2}
=====================

Look-Ups {#S2.SS1}
--------

### Selection of Relevant SNPs {#S2.SS1.SSS1}

Genome-wide significant SNPs (*P* ≤ 5 × 10^--8^) associated with (i) BMI (obesity), (ii) body composition, and/or (iii) body fat distribution ([Figure 1](#F1){ref-type="fig"}, search terms in [Supplementary Table S1](#TS1){ref-type="supplementary-material"}) were extracted from the GWAS Catalog version v1.0^[2](#footnote2){ref-type="fn"}^ ([@B139]) on 12 December 2017. GWAS Catalog provides uniform data sets (positions, genes, and systematized information on the studies).

![Flow chart of the conducted look-up analysis.](fgene-11-00373-g001){#F1}

The identified studies were independently reviewed by three authors (LL, TP, and JH) in order to exclude anthropometric traits that did not fit the purpose of the analysis. Single different ratings were resolved by consensus. This selection process resulted in the exclusion of some traits from further analyses with a focus on a disease (other than obesity), e.g., BMI in smokers, body mass in chronic obstructive pulmonary disease, BMI (change over time) in cancer, and osteoporosis.

The look-up of the identified SNPs was performed in March 2018 in publically available GWAS data sets for mental phenotypes, taking into account only studies that had identified at least one genome-wide significant locus as previously suggested ([@B46]). We added a more recent dataset for MDD because of the great importance of this disorder. Based on different consortia the following studies were included: (a) the Psychiatric Genetics Consortium (PGC)^[3](#footnote3){ref-type="fn"}^: schizophrenia ([@B115]), ADHD ([@B28]), BD ([@B123]), and ASD ([@B6]; downloaded between 22 November 2016 and 12 February 2017), AN ([@B32]; 26 September 2017), MDD ([@B143]; 2 May 2018); (b) the Social Science Genetic Association Consortium (SSGAC)^[4](#footnote4){ref-type="fn"}^: educational attainment ([@B97]), neuroticism, well-being, and depressive symptoms ([@B96]; 22 November to 12 December 2016); (c) Anxiety Neuro Genetics Study: anxiety disorder ([@B98]; 28 November 2016), (d) Complex Treat Genetic Lab (GTCLab): intelligence ([@B124]; 29 June 2017); (e) The Genetics of Personality Consortium (GPC): conscientiousness and openness ([@B25]; 27 September 2017); (f) The Centre for Cognitive Ageing and Cognitive Epidemiology (CCACE): tiredness ([@B26]; 19 October 2017; [Supplementary Table S3](#TS1){ref-type="supplementary-material"}).

To define independent loci we used a distance criterion of ±500 kb surrounding the middle SNP of a chromosomal locus ([@B72]). Consecutive numbers were assigned to each locus ([Supplementary Table S4](#TS1){ref-type="supplementary-material"}; for MDD loci see [Supplementary Table S5](#TS1){ref-type="supplementary-material"}). Furthermore, linkage disequilibrium (*r*^2^) was checked within each locus and, in case of linkage equilibrium between two SNPs (*D*′ \< 0.01, *r*^2^ \< 0.01)^[5](#footnote5){ref-type="fn"}^, these were regarded as independent loci.

Independent data sets for confirmatory look-up analyses were available for (a) educational attainment ([@B24]) \[*n* = 111,114, downloaded on 4 December 2017 ([@B64]), based on data from the CHARGE and COGENT consortia, and UK Biobank\]. These study groups are independent of the 65 study groups included in the study of [@B97]; and (b) neuroticism ([@B76]; UK Biobank sample size; *n* = 329,821; 17 April 2018; [Supplementary Table S3](#TS1){ref-type="supplementary-material"}).

Genome-wide association studies for mental phenotypes and anthropometric traits have been conducted with study groups that mainly included people of European descent. However, single anthropometric studies were performed in Japanese ([@B95]; [@B1]), African ([@B85]; [@B39]), and East-Asian populations ([@B140]).

To provide the reader with a synopsis, [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} were derived from [Supplementary Tables S4](#TS1){ref-type="supplementary-material"}, [S5](#TS1){ref-type="supplementary-material"}, which illustrate the complete results of the look-ups. [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} depict one representative SNP for each study-wide significant locus, which in case of loci tagged by \>1 SNP was identified by (1) if applicable, the highest number of mental phenotypes hits (*P* \< 4.98 × 10^--5^), (2) among these SNPs the one with the lowest *P*-value was chosen.

###### 

Results of look-up analyses for the lead anthropometric trait BMI.

  Locus No.   Lead SNP     Anthropometric trait/phenotype within the locus     Chromo-somal locus   Reported genes                                                                                    EdAtt             Intelligence      Schizo-phrenia    Bipolar disorder   ADHD      Depression symptoms   MDD           Neuroticism   Well-being   Effect direction^&^
  ----------- ------------ --------------------------------------------------- -------------------- ------------------------------------------------------------------------------------------------- ----------------- ----------------- ----------------- ------------------ --------- --------------------- ------------- ------------- ------------ -----------------------------------------------------------------------------------
  1           rs3101336    BMI, obesity, WC, and HC                            1p31.1               *NEGR1, LINC01360, KRT8P21*                                                                       9.7E−07           4.0E−07                                                          1.3E−05^\#^           **8.0E−08**                              C: BMI↑, Obesity↑, HC↑, WC↑, IQ↑, EdAtt↑, MDD↑, and Depression↑
                                                                                                                                                                                                                                                                                                                                                        
  2           rs12401738   BMI, obesity, WC, and HC                            1p31.1               *FUBP1, ZZZ3, DNAJB4*                                                                             5.2E−07                                                                                                                                           A: BMI↑, HC↑, WC↑, and EdAtt↓
                                                                                                                                                                                                                                                                                                                                                        
  3           rs1561288    BMI, obesity, HC, and WC~adjBMI~                    2p23.3               *POMC*                                                                                                                                1.4E−05                                                                                                       C: BMI↑, HC (n.s.), WC~adjBMI~↓\*, SZP↓
                                                                                                                                                                                                                                                                                                                                                        
  4           rs7613875    BMI                                                 3p21.31              *MON1A, RBM6*                                                                                     **4.4E**−**16**                                                                                                                                   A: BMI↑ and EdAtt↓
                                                                                                                                                                                                                                                                                                                                                        
  5           rs2710323    BMI, WHR, WC~adjBMI~, HC~adjBMI~, and WHR~adjBMI~   3p21.1               *NT5DC2, PBRM1, ITIH1, NEK4, ITIH3, ITIH4*                                                                                            **9.1E**−**11**   3.7E−06                                                                                     T: BMI↓, WHR↑\*, WC~adjBMI~↑, HC~adjBMI~ (n.s.), WHR~adjBMI~↑, SZP↑, and Bipolar↑
                                                                                                                                                                                                                                                                                                                                                        
  6           rs2325036    BMI, obesity, WC, and HC                            3p12.1               *CADM2*                                                                                           1.8E−07                                                                                                                                           A: BMI↑,WC↑, HC↑, and EdAtt↓
                                                                                                                                                                                                                                                                                                                                                        
  7           rs7621025    BMI and WC~adjBMI~                                  3q22.3               *STAG1*                                                                                                                               9.3E−06                                                                                                       C: BMI↑, WC~adjBMI~ (n.s.), and SZP↓
                                                                                                                                                                                                                                                                                                                                                        
  8           rs1516725    BMI, obesity, WC, HC, and HC~adjBMI~                3q27.2               *ETV5*                                                                                            1.5E−05                                                                                                                                           C: BMI↑, obesity↑, WC↑, HC↑, HC~adjBMI~ ↓\*, and EdAtt↑
                                                                                                                                                                                                                                                                                                                                                        
  9           rs13107325   BMI                                                 4q24                 *SLC39A8*                                                                                                           1.1E−07           **1.5E**−**12**                                                                                               T: BMI↑, SZP↑, and IQ↓
                                                                                                                                                                                                                                                                                                                                                        
  10          rs7720894    BMI                                                 5q12.1               *ZSWIM6*                                                                                          **5.0E**−**09**                     **1.2E**−**10**                                                                                               C: BMI↓, EdAtt↓, and SZP↑
                                                                                                                                                                                                                                                                                                                                                        
  11          rs1846974    BMI                                                 5q14.3               *LINC00461, LOC645323*                                                                            6.6E−06                                                                                                                3.1E-06                    A: BMI↑. EdAtt↑, and Nt↑
                                                                                                                                                                                                                                                                                                                                                        
  12          rs40067      BMI and WC~adjBMI~                                  5q21.3               *FBXL17*                                                                                                                                                                   1.6E−05                                                                  G: BMI↑, WC~adjBMI~ (n.s.), and ADHD↑
                                                                                                                                                                                                                                                                                                                                                        
  13          rs329120     BMI                                                 5q31.1               *JADE2*                                                                                           3.9E-07                                                                                                                                           T: BMI↓ and EdAtt↑
                                                                                                                                                                                                                                                                                                                                                        
  14          rs3800229    BMI, WC and HC                                      6q21                 *FOXO3, FOXO3A*                                                                                                     **5.4E**−**10**   1.1E−07                                                                                                       T: BMI↑, WC↑, HC↑, IQ↑, and SZP↓
                                                                                                                                                                                                                                                                                                                                                        
  15          rs2185027    BMI                                                 6q25.2               *RGS17*                                                                                           2.9E−05                                                                                                                                           C: BMI↑ and EdAtt↓
                                                                                                                                                                                                                                                                                                                                                        
  16          rs7779181    BMI                                                 7p14.3               *PDE1C, LOC100130673*                                                                                               2.5E−06                                                                                                                         C: BMI↑ and IQ↓
                                                                                                                                                                                                                                                                                                                                                        
  17          rs10811901   BMI                                                 9p21.3               *LINC01239, LOC101929563*                                                                         **9.5E**−**12**                                                                                                                                   A: BMI↑ and EdAtt↑
                                                                                                                                                                                                                                                                                                                                                        
  18          rs2163188    BMI                                                 10q21.3              *REEP3*                                                                                           **2.7E**−**08**                                                                                                                                   C: BMI↑ and EdAtt↓
                                                                                                                                                                                                                                                                                                                                                        
  19          rs4409766    BMI, WC, HC, WC~adjBMI~ and HC~adjBMI~              10q24.32             *ASMT/C10orf32, CYP17A1*                                                                                                              **1.9E**−**11**                                                      1.9E−05                                  C: BMI↑, HC↑, WC↑, WC~adjBMI~ (n.s.), WHR~adjBMI~ (n.s.), SZP↓, and MDD↓
                                                                                                                                                                                                                                                                                                                                                        
  20          rs11191560   BMI                                                 10q24.33             *NT5C2*                                                                                                                               **6.3E**−**16**                                                      3.6E−05                                  C: BMI↑, SZP↓, and MDD↓
                                                                                                                                                                                                                                                                                                                                                        
  21          rs10838738   BMI, WC, and HC                                     11p11.2              *MTCH2, FNBP4*                                                                                                                                                                                                           3.0E−06                    G: BMI↑, HC↑, WC↑ and Nt↓
                                                                                                                                                                                                                                                                                                                                                        
  22          rs7123876    BMI                                                 11q13.4              *ARAP1*                                                                                           3.3E−06                                                                                                                                           C: BMI↑ and EdAtt↓
                                                                                                                                                                                                                                                                                                                                                        
  23          rs1569980    BMI and WC                                          14q12                *PRKD1, MIR548AI*                                                                                 6.4E−07                                                                                                                                           C: BMI↑, WC↑\*, and EdAtt↓
                                                                                                                                                                                                                                                                                                                                                        
  24          rs17522122   BMI                                                 14q12                *AKAP6, NPAS3*                                                                                                                        4.7E−06                                                                                                       T: BMI↑ and SZP↑
                                                                                                                                                                                                                                                                                                                                                        
  25          rs1559677    BMI                                                 15q21.1              *SEMA6D*                                                                                                                              1.0E−05                                                                                                       G: BMI↑, SZP↑
                                                                                                                                                                                                                                                                                                                                                        
  26          rs2008514    BMI, obesity, BF%^§^, WC, HC and HC~adjBMI~         16p11.2              *IL27, NUPR1, ATP2A1, SH2B1, APOB48R, SULT1A2, AC138894.2, ATXN2L, SBK1 TUFM,ATP2A1-AS1 RABEP2*   **9.4E**−**09**   **1.5E**−**08**                                                                                                                 A: BMI↑, BF↑, WC↑, HC↑, HC~adjBMI~↑, EdAtt ↓, and IQ↓
                                                                                                                                                                                                                                                                                                                                                        
  27          rs2281727    BMI                                                 17p13.3              *SMG6*                                                                                                                                **3.6E**−**08**                                                                                               G: BMI↑ and SZP↓
                                                                                                                                                                                                                                                                                                                                                        
  28          rs4925114    BMI and HC                                          17p11.2              *RAI1*                                                                                                                                1.2E−07                                                                                                       G: BMI↑, HC↑, and SZP↓
                                                                                                                                                                                                                                                                                                                                                        
  29          rs12150665   BMI                                                 17q12                *GGNBP2*                                                                                                            2.0E−06                                                                                                                         C: BMI↓ and IQ↑
                                                                                                                                                                                                                                                                                                                                                        
  31          rs8092503    BMI                                                 18q21.2              *RAB27B, DYNAP*                                                                                                                                                                                            6.9E−06                     3.7E−05      A: BMI↓, MDD↑, and WB↓
                                                                                                                                                                                                                                                                                                                                                        
  32          rs2331841    BMI, obesity, BF%^§^, BFM^£^, WC, HC, and WHR       18q21.32             *MC4R*                                                                                                                                                                                                                   3.3E−05                    A: BMI↑, BF%↑\*, WC↑, HC↑, WHR↑, and Nt↓
                                                                                                                                                                                                                                                                                                                                                        
  33          rs427943     BMI                                                 21q22.3              *ADARB1*                                                                                                                                                                                                   3.1E−05                                  C: BMI↑ and MDD↑
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###### 

BMI independent loci associated with measures of body fat distribution adjusted for BMI (WC adjusted for BMI: WC~adjBMI~; HC adjusted for BMI: HC~adjBMI~; and WHR adjusted for BMI: WHC~adjBMI~; for complete overview of the results see [Supplementary Table S4](#TS1){ref-type="supplementary-material"}).

  Locus No.   Lead SNP     Anthropometric trait/phenotype within the locus   Chromosomal locus   Reported genes     EdAtt             Intelligence   Schizophrenia     Effect direction^&^
  ----------- ------------ ------------------------------------------------- ------------------- ------------------ ----------------- -------------- ----------------- ----------------------------------------
  34          rs615672     WC~adjBMI~ and WHR~adjBMI~                        6p21.32             *HLA-DRB1*                                          5.7E−07           G: WC~adjBMI~↑, WHR~adjBMI~↑, and SZP↑
                                                                                                                                                                       
  35          rs11156429   WC~adjBMI~ and HC~adjBMI~                         6q16.3              *HACE1*                                             2.3E−06           T: WC~adjBMI~↑, HC~adjBMI~↑, and SZP↑
                                                                                                                                                                       
  36          rs1538170    HC~adjBMI~                                        6q22.32             *CENPW*                              4.9E−05                          T: HC~adjBMI~↑, IQ↑
                                                                                                                                                                       
  37          rs1144       WC~adjBMI~                                        7q22.3              *SRPK2*                                             1.3E−06           T: WC~adjBMI~↓ and SZP↓
                                                                                                                                                                       
  38          rs1727294    HC~adjBMI~                                        12q24.31            *PITPNM2*          **9.1E**−**14**   3.4E−05        **4.7E**−**09**   A: HC~adjBMI~↑, EdAtt↑, IQ↑, and SZP↑
                                                                                                                                                                       
  39          rs4765219    WC~adjBMI~ and WHR~adjBMI~                        12q24.31            *DNAH10, CCDC92*                                    1.8E−05           C: WC~adjBMI~↑, WHR~adjBMI~↑, and SZP↓
                                                                                                                                                                       
  40          rs181553     HC~adjBMI~                                        18q21.1             *DYM*                                               3.6E−06           A: HC~adjBMI~↑ and SZP↑

BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip ratio; MDD, major depressive disorder; IQ, intelligence; EdAtt, educational attainment; SZP, schizophrenia; WB, well-being; adjBMI, adjusted for BMI;

&

upward arrows indicate positive beta-values or odds ratios \>1, downward arrows negative beta-values or odds ratios \<1; P-values \>5 × 10−

8

(genome-wide significant) are shown in bold.

Based on supplementary files and summary statistics effect directions of the alleles for mental phenotypes and the anthropometric traits were described for each representative SNP (*P* \< 4.98 × 10^--5^)^[6](#footnote6){ref-type="fn"},[7](#footnote7){ref-type="fn"}^. In addition, the effect directions of the alleles were included for each anthropometric trait, for which that particular locus showed at least one hit. For this purpose, summary statistics for HC, WC, WHR, HC~adjBMI~, WC~adjBMI~, WHR~adjBMI~ ([@B122]; European descent and sex-combined), BF% ([@B75]), and BMI (European descent; [@B72]; [@B146]) were used.

If a SNP for BMI was found only in a GWAS study based on participants of non-European descent, we reviewed the effect directions and allele frequencies in GWAS of European descent ([@B72]; [@B146]). Summary statistics were downloaded on 30 January 2018 for BMI ([@B72]) on 14 February 2019, for BMI ([@B146]) on 26 February 2019 for WC, WHR, HC~adjBMI~, WC~adjBMI~, and WHR~adjBMI~ ([@B122]); for BF% ([@B75]) on 26 February 2019^[8](#footnote8){ref-type="fn"},[9](#footnote9){ref-type="fn"}^.

### Statistical Analyses {#S2.SS1.SSS2}

To control for the overall type I error rate in the look-up, Bonferroni correction was applied. We assumed a univariate multiple regression model for each mental phenotype and independence of SNPs. This entailed a Bonferroni correction for 1,005 tests (1,005 SNPs), resulting in a threshold *P*-value of 4.98 × 10^--5^. We did not prune SNPs in high LD to adhere to a conservative approach. For confirmatory analyses, the same *P*-value (4.98 × 10^--5^) was considered as significant.

Mendelian Randomization {#S2.SS2}
-----------------------

We performed a Mendelian randomization study to exemplarily investigate the causality between body fat distribution and schizophrenia. Body fat distribution data were obtained from the latest GWAS analysis ([@B107]; 694,649 individuals), which explained about 3.9% of the variance in WHR~adjBMI~. As data source for the risk for schizophrenia the GWAS analysis; with 40,675 cases and 64,643 controls (145 independent loci) was used ([@B99]). SNP-based heritability was estimated at 24% ([@B99]; [@B104]). We conducted a two-sample MR analysis with WHR as risk factor (exposure) and schizophrenia as outcome variable and the reverse analysis. In order to conduct a MR study, three core assumptions must be fulfilled ([@B44]; [@B59]). Therefore, we conducted an *F*-test to test the weakness of the instrument ([@B27]; [@B17]). We examined horizontal pleiotropy by estimating the intercept of Egger's regression ([@B18]). To test heterogeneity of the instrument variable, we used Cochran's Q-statistic.

We carried out MR using two statistical methods to estimate overall ratio effects: the inverse-variance weighted method (IVW) and the MR-Egger method. IVW assumes that the all ratio estimates provide independent evidence on the causal effect and there is no pleiotropic effect. So IVW assumes that all genetic variants are valid instrumental variables. There is no intercept term in the regression model ([@B18]). In MR-Egger the intercept term is estimated as part of the analyses. The intercept term can be interpreted as the average pleiotropic effect of a genetic variant included in the analyses. A non-zero intercept from MR-Egger shows that there is directional pleiotropy, or that instrumental variable assumptions are violated, or both ([@B18]). Consideration of MR-Egger estimates and intercept terms, and comparison of IVW and MR-Egger estimates is helpful to interpret results of a MR analysis ([@B18]).

We performed a power analysis to estimate whether our analysis, given sample size, proportion of cases in the study and the proportion of variance explained, is sufficient to detect a true casual effect ([@B14]). In order to investigate the relationship between study accuracy and effect size, we created a funnel plot ([@B44]; [@B53]). To examine whether an individual data point (SNP) has a large influence on the regression coefficients, we calculated the IVW regression by leaving each genetic variant out in turn ([@B18]). To visualize the results, forest and scatter plots were used. We also performed MR with Robust Adjusted Profile Score (RAPS), which estimator is more robust to pleiotropy ([@B149]). All tests were performed using the software "R," version 3.5.2 and R-packages for performing 2-sample MR^[10](#footnote10){ref-type="fn"}^ and RAPS.^[11](#footnote11){ref-type="fn"},[12](#footnote12){ref-type="fn"}^

Results {#S3}
=======

Look-Ups {#S3.SS1}
--------

A total of 1,005 genome-wide significant (*P* ≤ 5 × 10^--8^) SNPs from 56 studies were identified for BMI/obesity, body composition, and/or body fat distribution ([Supplementary Table S2](#TS1){ref-type="supplementary-material"}). Upon Bonferroni correction for multiple testing (*P* \< 4.98 × 10^--5^), 82 SNPs at 40 genomic loci were associated with one or more mental phenotypes ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}; see [Supplementary Tables S4](#TS1){ref-type="supplementary-material"}, [S5](#TS1){ref-type="supplementary-material"} for complete overview), among which the four mental phenotypes educational attainment (16 loci), intelligence (7 loci), schizophrenia (18 loci), and MDD (5 loci) figured prominently. Single loci only were detected for BD, neuroticism, ADHD, depressive symptoms, and well-being. No hits were detected for the remaining six phenotypes (ASD, AN, anxiety, tiredness, conscientiousness, and openness).

For eleven loci, significant hits (*P* \< 4.98 × 10^--5^) for more than one mental phenotype -- mainly encompassing educational attainment, intelligence and schizophrenia -- were identified. Locus 1p31.1 (rs3101336, rs7550173, and comprising *NEGR1*) was significantly associated with the maximal number of four phenotypes (educational attainment, intelligence, depressive symptoms, and MDD).

The seven of the 40 loci that were not identified via BMI SNPs pertained to different measures of body fat distribution adjusted for BMI (WC~adjBMI~, HC~adjBMI~, and/or WHR~adjBMI~; [Table 2](#T2){ref-type="table"}). All but one locus were associated with schizophrenia.

We analyzed effect directions of all alleles of significant SNPs (*P* \< 4.98 × 10^--5^). For the SNPs in [Table 1](#T1){ref-type="table"}, we looked up the effect directions for all phenotypes in respective locus (BMI, body composition, body fat distribution, and mental phenotypes) in the respective summary statistics ([@B72]; [@B122]; [@B75]; [@B146]). As expected, the effect directions were always identical for BMI, obesity, non-adjusted HC and WC, respectively.

[Table 3](#T3){ref-type="table"} provides an overview of the effect directions of all detected significant (*P* \< 4.98 × 10^--5^) SNP associations separated according to associations with BMI (irrespective of additional associations to other traits; for loci see [Table 1](#T1){ref-type="table"}) or with unique associations pertaining to BMI adjusted measures (for loci see [Table 2](#T2){ref-type="table"}). Opposite effect directions of alleles associated with a higher BMI were observed twice as often for educational attainment, intelligence, and schizophrenia than concordant directions.

###### 

Overview of effect directions at the genetic loci for BMI/obesity (see [Table 1](#T1){ref-type="table"}).

  Phenotypes                   Number of loci with effect directions in the same and opposite directions   
  ---------------------------- --------------------------------------------------------------------------- ----
  **Educational attainment**                                                                               
  BMI                          5                                                                           10
  Measures adjusted for BMI    1                                                                           0
  **Intelligence**                                                                                         
  BMI                          2                                                                           4
  Measures adjusted for BMI    2                                                                           0
  **Schizophrenia**                                                                                        
  BMI                          4                                                                           8
  Measures adjusted for BMI    5                                                                           1
  **Bipolar disorder**                                                                                     
  BMI                          1                                                                           1
  Measures adjusted for BMI    0                                                                           0
  **ADHD**                                                                                                 
  BMI                          1                                                                           0
  Measures adjusted for BMI    0                                                                           0
  **Depressive symptoms**                                                                                  
  BMI                          1                                                                           0
  Measures adjusted for BMI    0                                                                           0
  **MDD**                                                                                                  
  BMI                          2                                                                           3
  Measures adjusted for BMI    0                                                                           0
  **Neuroticism**                                                                                          
  BMI                          1                                                                           2
  Measures adjusted for BMI    0                                                                           0

Anthropometric measures adjusted for BMI (WHR

adjBMI

, WC

adjBMI

, and HC

adjBMI

; see

Table 2

) and mental phenotypes; loci listed for measures adjusted for BMI refer to the total of seven loci uniquely identified via these adjusted measures. Upward arrows indicate positive beta-values or odds ratios \>1, downward arrows negative beta-values or odds ratios \<1. BMI, body mass index; all BMI dependent body measures.

Confirmatory Analyses {#S3.SS2}
---------------------

We performed confirmatory look-up analyses for educational attainment and neuroticism in the most recent and independent GWAS datasets for SNPs that fulfilled our *P*-value threshold of *P* \< 4.98 × 10^--5^. No independent data sets were available for other mental phenotypes ([Supplementary Table S3](#TS1){ref-type="supplementary-material"}). Twenty two of the 38 SNPs for educational attainment revealed *P*-values below *P* \< 4.98 × 10^--5^ (10 of 15 loci). For neuroticism, five of seven SNPs (three of four independent loci) were confirmed in an independent dataset ([Supplementary Table S6](#TS1){ref-type="supplementary-material"}).

Mendelian Randomization {#S3.SS3}
-----------------------

We performed a MR analysis to investigate the causal effect of body fat distribution, measured as WHR~adjBMI~, on risk of schizophrenia (for data on the 328 genome wide significant SNPs associated with WHR~adjBMI~, see [Supplementary Table S9](#TS1){ref-type="supplementary-material"}). With *F* = 85.907 the *F*-statistic indicates strong instrumental variables. After removing palindromic and ambiguous SNPs (*n* = 9), we included 319 SNPs in the analysis. The overall estimates, calculated by IVW or MR Egger, did not reveal associations between WHR~adjBMI~ and risk of schizophrenia (IVW, *b* = 0.0062, *P* = 0.9107; [Supplementary Table S10](#TS1){ref-type="supplementary-material"} and [Supplementary Figures S4](#FS1){ref-type="supplementary-material"}--[S6](#FS1){ref-type="supplementary-material"}), although in the single SNP analyses, 47 SNPs showed a significant result ([Supplementary Table S11](#TS1){ref-type="supplementary-material"}). Sensitivity analyses using the leave-one-out approach confirmed the lack of associations ([Supplementary Figure S7](#FS1){ref-type="supplementary-material"}). There was no evidence for pleiotropy (MR-Egger intercept = −0.0003194; *P* = 0.8991). The heterogeneity test was significant \[*Q*(*df* = 317) = 860.0176, *P* = 1.12 × 10^--51^\]. Power analysis revealed that our MR analyses had an 80% power to detect an odds ratio (OR) of 1.09 and 100% power to detect an OR of 1.28 for schizophrenia ([Supplementary Figure S8](#FS1){ref-type="supplementary-material"}). The more robust method RAPS also showed no causal effect of body fat distribution on schizophrenia \[RAPS main function: beta(hat) = 0.0059, SE = 0.03291, *P* = 0.858; RAPS overdispersed function: beta(hat) = −0.0744, SE = 0.1115, *P* = 0.504\].

To test reverse causality, we performed an MR analysis where we considered the risk of schizophrenia as a risk factor (for information on the association of 142 SNPs, see [Supplementary Table S12](#TS1){ref-type="supplementary-material"}) and WHR~adjBMI~ as an outcome. After removing palindromic and ambiguous SNPs (*n* = 4), we included 138 SNPs in the analysis. *F*-test revealed that the instruments were strong (*F* = 233.896). The heterogeneity test was significant \[*Q*(*df* = 136) = 771.8842, *P* = 1.60 × 10^--89^\], as was the test for directional horizontal pleiotropy (MR-Egger intercept = 0.00539, *P* = 0.0077). Consequently, we must assume pleiotropy, so that further results must be assumed to be biased. Single SNP analyses revealed that 46 SNPs showed a significant causal effect on WHR~adjBMI~ with opposite effect directions The overall MR analysis with the Egger-method revealed a causal effect of schizophrenia on WHR~adjBMI~ (*b* = −0.073, *P* = 0.0098), the IVW-method, however, showed no significant effect (*P* = 0.9296; [Supplementary Tables S13](#TS1){ref-type="supplementary-material"}, [S14](#TS1){ref-type="supplementary-material"} and [Supplementary Figures S9](#FS1){ref-type="supplementary-material"}--[S11](#FS1){ref-type="supplementary-material"}). RAPS method showed no effect \[main function: beta(hat) = 0.0007, SE = 0.0025, *P* = 0.790; overdispersed function: beta(hat) = −0.0055, SE = 0.0076, *P* = 0.473\].

Discussion {#S4}
==========

We identified 82 SNPs at 40 independent loci for (i) BMI (including obesity), (ii) body composition (BFM and BF%), and/or (iii) body fat distribution (WC, HC, and WHR; adjusted and unadjusted for BMI) concomitantly associated with mental phenotypes. The majority of locus associations were detected with educational attainment (*n* = 16), intelligence (*n* = 7), schizophrenia (*n* = 18), and MDD (*n* = 5). The fact that we found only five loci (1p31.1, 10q24.32, 10q24.33, 18q21.2, and 21q22.3) common for MDD could be due to the relatively low heritability, phenotypic heterogeneity, and multifactorial etiopathogenesis of this disorder ([@B65]; [@B89]; [@B84]).

The potential relevance of the identified loci seems to be substantiated by the fact that (a) 15 SNPs loci (seven for schizophrenia, six for educational attainment, and two for intelligence) at 12 loci met the genome-wide significance threshold and (b) 11 of 18 loci were confirmed for intelligence and neuroticism in independent data sets. Nevertheless, future GWAS and meta-analyses will need to show that our significant hits with *P*-values between *P* \< 4.98 × 10^--5^ and 5 × 10^--8^ indeed represent true findings for the respective mental phenotypes.

Thirty-three loci associated with mental phenotypes were identified via BMI/obesity SNPs ([Table 1](#T1){ref-type="table"}); for 16 of these loci, the same or additional SNPs identified via other anthropometric traits were co-localized. Thus, as expected based on high correlations between the anthropometric traits ([@B118]) the SNPs for BMI unadjusted traits of body composition and body fat distribution (WC, HC, WHR, BF%, and BFM) associated with mental phenotypes were always co-associated with the loci identified via BMI SNPs. Only seven loci were unique for BMI adjusted measures of body fat distribution ([Table 2](#T2){ref-type="table"}). Because of the co-occurrence of nine loci identified both via BMI and measures of body fat distribution adjusted for BMI, we looked up the lead SNPs of these seven loci ([Table 2](#T2){ref-type="table"}) in the most recent GWAS meta-analyses for BMI ([@B146]; [Supplementary Table S7](#TS1){ref-type="supplementary-material"}); interestingly, all but one locus (locus no. 38: rs1727294) revealed a *P*-value \<0.05, one of which was even genome-wide significant (locus no. 39: rs12317176). Clearly, the overall frequent co-identification of loci for BMI and BMI adjusted measures of body fat distribution indicates an overlap between BMI and BMI adjusted body fat distribution loci with respect to the respective mental phenotypes.

Recently, [@B54] conducted look-up analyses in several somatic and mental disorders using genome wide significant WHR~adjBMI~ SNPs as measurement for body fat distribution/abdominal obesity. In accordance with our results, they found that two WHR~adjBMI~ variants in 3p21.1 (see locus 5 in [Table 1](#T1){ref-type="table"}) are associated with schizophrenia (*PBMI1* and *ITIH1*) and BD (*ITIH1*) ([@B54]); our results indicate that BMI, HC~adjBMI~, and WC~adjBMI~, too, are associated with these mental disorders. Additionally, they reported that *LOC105375015* (rs2596500) was associated with WHR~adjBMI~ and schizophrenia, a finding we could not confirm as our analyses did not include proxy SNPs.

There are numerous indications that the clinical association between abdominal obesity and cardiometabolic risk is largely independent of BMI ([@B30]; [@B133]). For the latest genetic study on body fat distribution (WHR~adjBMI~; [@B107]), the potential for collider bias resulting from conditioning WHR on BMI was analyzed. They found that most WHR~adjBMI~ SNPs (311 of 346) are associated with stronger standard deviation effect sizes for WHR than for BMI. Each additional (weighted) WHR~adjBMI~-raising allele was associated with a higher WHR and with a lower BMI ([@B107]). We looked up the 346 SNPs associated with WHR~adjBMI~ ([@B107]) in the recent GWAS for BMI ([@B146]): 263 SNPs overlapped between the two data sets ([@B146]; [@B107]), 20 of which were genome-wide significant for both WHR~adjBMI~ and BMI. In light of the high number of SNPs identified in our study that have an effect on both BMI and WHR~adjBMI~ and the less than 10% overlap (20/263) of BMI and WHR~adjBMI~ ([@B146]; [@B107]). SNPs we postulate that loci having independent effects on both anthropometric traits have a higher probability of playing a role in mental phenotypes.

Our data indicate that the associations between anthropometric traits and mental disorders/traits are heterogeneous as some effects were directionally consistent and for others the risk alleles pointed to opposite directions ([Table 3](#T3){ref-type="table"}). As expected, effect directions for BMI, obesity, HC, and WC were consistent for all the respective 16 loci; for the two loci (nos. 5 and 32; [Table 1](#T1){ref-type="table"}) co-identified by WHR one effect directions was concordant, the other discordant to BMI. The overall associations between genetic risks for different diseases or genetic proportion of variance across all SNPs are expressed with genetic correlations or correlations between genetic risk scores. Small to medium, but nevertheless significant genetic correlations have been detected between BMI and schizophrenia (*r*~*g*~ = −0.10, *P* = 1.7 × 10^--4^) ([@B15]), BMI and ADHD (*r*~*g*~ = 0.26, *P* = 3.0 × 10^--3^), BMI and childhood intelligence (*r*~*g*~ = −0.17, *P* = 2.3 × 0^--3^) ([@B15]), BMI and intelligence (*r*~*g*~ = −0.16, *P* = 1.4 × 10^--16^) ([@B47]), BMI and educational attainment (*r*~*g*~ = −0.28, *P* = 6.6 × 10^--16^) ([@B15]), and BMI and AN (*r*~*g*~ = −0.18, *P* = 3.17 × 10^--7^) ([@B15]; [@B47]). Between WC or WHR and educational attainment genetic correlations of −0.29 (*P* = 2.31 × 10^--14^) and −0.33 (*P* = 1.34 × 10^--18^) were reported ([@B15]). The correlations between genetic risk scores for both schizophrenia and educational attainment with BF% were negative (*P* \< 0.05; [@B113]). We were unable to find studies providing genetic correlations between BMI, body composition, and body fat distribution traits.

For schizophrenia, we identified the strongest overlap with body fat distribution traits adjusted for BMI in our look-up analysis ([Table 2](#T2){ref-type="table"}). Most clinical studies ([@B130]; [@B58]; [@B129]), but not all ([@B55]) have found a higher BF%, BFM, visceral adipose tissue mass in normal weight patients with schizophrenia as compared to healthy controls. These clinical observational studies either considered antipsychotic medication as a covariable ([@B129]), discuss it as a justification for observed differences ([@B55]), or mention the inclusion of patients on antipsychotics as a limitation ([@B130]). Besides general limitations of observational studies such as residual confounding, directions of potential causal links between body fat distribution and schizophrenia remain unclear. MR assumes that genetic variants are not confounded by behavioral, socioeconomic, and physiological factors and genetic variants will not be influenced by the onset of disease ([@B23]). Therefore, MR can be regarded as a randomized controlled trial provided by nature. For this reason, we applied MR analysis to the most recent data to test whether there is an overall causal association between BMI adjusted body fat distribution and schizophrenia.

The MR analysis did not reveal evidence for an overarching effect of adjusted body fat distribution on the risk for this mental disorder. The power analysis revealed that our MR had a 100% power to detect an OR of 1.28 for schizophrenia. This OR is similar as those observed for single SNPs calculated in GWAS: e.g., the T-allele of rs3130820 (the SNP with the highest effect in GWAS by [@B99]) increases the risk of getting a diagnosis of schizophrenia by 1.281 times (SE = 0.018, *P* = 2.12 × 10^--44^); the OR of the T-allele at rs12416331 is 1.157 (SE = 0.017, *P* = 7.09 × 10^--18^). Thus, the power of our MR was sufficient to detect a clinically relevant risk for schizophrenia. In the reverse analyses about the causal effect of schizophrenia on body fat distribution, the non-zero intercept from MR-Egger indicates that there is the directional pleiotropy or the assumptions for instrumental variable are violated, or both. The Egger method showed a significant effect, but the IVW method showed none. The RAPS method, which is more robust to pleiotropy, showed no effect. Our MR analyses suggest that there is no causal effect of schizophrenia on body fat distribution.

Our study now shows that specific genetic effects at individual loci may well play a role in associations between both BMI adjusted body fat distribution and schizophrenia.

In the following, we provide the reader with an insight into potential functional implications of five of the 40 loci which we deem of particular interest^[13](#footnote13){ref-type="fn"},[14](#footnote14){ref-type="fn"},[15](#footnote15){ref-type="fn"},[16](#footnote16){ref-type="fn"},[17](#footnote17){ref-type="fn"},[18](#footnote18){ref-type="fn"}^ ^:^

1.  Locus 1p31.1 (rs3101336, rs7550173, *NEGR1;* locus 1 in [Table 1](#T1){ref-type="table"}) was significantly associated with both MDD and depressive symptoms, educational attainment, and intelligence. *NEGR1* (neuronal growth regulator 1 gene), a well-known obesity-associated gene ([@B141]), is associated with white matter integrity ([@B29]), and shows high expression in several brain tissues (highest median expression in frontal cortex, [Supplementary Figure S1](#FS1){ref-type="supplementary-material"}). *NEGR1* is a member of the immunoglobulin domain-containing glycosylphosphatidylinositol (GPI)-anchored neural cell adhesion molecules (IgLON; [@B52]) and involved in neural cell communication and synapse formation ([@B50]). Recently, *NEGR1* was also found to play a role in intracellular cholesterol trafficking ([@B50]). Overall, *NEGR1* seems to play a pleiotropic role due to its involvement in synaptogenesis, neuron maturation, and neurite outgrowth, which all represent essential mechanisms for sustaining brain function and development ([@B106]). Significantly, elevated levels of *NEGR1* transcripts were found in the dorsolateral prefrontal cortex of patients with schizophrenia compared to healthy controls ([@B52]).

2.  *CYP17A1* (cytochrome P450 family 17 subfamily a member 1 gene) in 10q24.33 (locus 19 in [Table 1](#T1){ref-type="table"}) is one of the well-known genes associated with adult hypertension ([@B66]). We found an association with BMI, WC, HC, WC~adjBMI~, HC~adjBMI~, and both schizophrenia and MDD. *CYP17A1* has previously been found to be associated with schizophrenia ([@B115]); our detected association is novel for MDD. In the recently published multivariate study on the wellbeing spectrum, *CYP17A1* was associated with depressive symptoms and neuroticism ([@B7]). A potentially overarching functional implication of this locus in both somatic and mental disorders is supported ([@B134]) by the fact that in adolescent males but not females, a *CYP17A1* SNP was associated with enhanced blood pressure reactivity to mental stress ([@B134]). *CYP17A1* is predominantly expressed in adrenal glands ([Supplementary Figure S2](#FS1){ref-type="supplementary-material"}) and is a bi-functional key regulatory enzyme in the steroidogenic pathway with 17α-hydroxylase and 17,20-lyase activity ([@B148]). *CYP17A1* is essential for the formation of all endogenous androgens ([@B102]) and many glucocorticoids ([@B57]). Key substrates are pregnenolone and progesterone, which are transformed to the androgen precursor's dehydroepiandrosterone and androstenedione ([@B56]). Several findings indicate a sex-related susceptibility for schizophrenia with males at higher risk, e.g., earlier age of onset compared to a lower susceptibility for women due to a potentially neuroprotective role of estrogens ([@B119]) via effects on dopamine (DA) neurotransmission ([@B31]; [@B117]; [@B35]; [@B38]). It is hypothesized that androgenic metabolites of testosterone, especially dihydrotestosterone (DHT) and androstenedione, may facilitate the development of schizophrenia-related symptoms. Quantitative real-time PCR in post-mortem brain slices of MDD patients showed a significant decrease in mRNA levels of CYP17A1 ([@B108]) and genetic variants of the rs743572 polymorphism of CYP17A1 were correlated with the intensity of depressive symptoms in post-menopausal women ([@B73]), altogether suggesting a role of CYP17A1 in mood disorders.

3.  At the locus 16p.11.2 (see locus 26 in [Table 1](#T1){ref-type="table"}) higher BMI, BF%, WC, HC, HC~adjBMI~, and higher risk for obesity were negatively associated with intelligence and educational attainment in line with previous evidence ([@B49]). Genetic variations \[SNPs, copy number variants (CNVs), and larger deletions/insertions\] at 16p.11.2 have been shown to be associated with developmental delay, ASD, ADHD, schizophrenia, BD, epilepsy, intracranial volume, brain development, congenital anomalies, altered satiety response, energy imbalance, underweight, and morbid obesity ([@B82]; [@B12]; [@B34]; [@B137]; [@B49]; [@B135]; [@B151]; [@B33]; [@B109]; [@B136]; [@B80]; [@B37]; [@B81]; [@B126]; [@B91]). The consequences of 16p11.2 CNV and larger deletions and duplications on health are broad ([@B22]; [@B91]). Because the CNVs are rare ([@B128]), large studies and complex analytical methods are needed to detect them in GWAS ([@B94]).

    The SNPs we found in 16p11.2 are assigned to genes *IL27, NUPR1, ATXN2L, SH2B1, TUFM, SBK1, SULT1A2, ATP2A1, APOB48R, AC138894.2, ATP2A1-AS1*, and *RABEP2* (see [Supplementary Table S6](#TS1){ref-type="supplementary-material"}); however, a total of 41 genes may be affected by the CNV in this region ([@B128]). The protein encoded by *IL27 (Interleukin 27)* is one of the subunits of a heterodimeric cytokine complex and is in many aspects closely tied to the cytokines IL-12 and IL-23. IL-27 may play a role in the rapid initiation of a response to an inflammatory challenge ([@B105]). Neuro-inflammatory processes as a result of stress-induced immune system activation ([@B43]) are discussed as potential mechanisms in the pathogenesis of mental disorders, e.g., depression ([@B8]). This hypothesis was recently supported by systems genomics studies ([@B121]) and clinical intervention studies with COX-2 inhibitors and aspirin ([@B88]). A negative phenotypical correlation of the level of systemic inflammation biomarkers with general intelligence in children also has been observed ([@B63]). Inflammation and metabolic risk factors might increase the risk of psychosis in some people ([@B103]), inflammatory mechanisms may also play a role in the pathophysiology of stress-related and anxiety disorders ([@B60]).

4.  In 3p12.1 we found an association between BMI (obesity) and educational attainment (rs2325036, *CADM2*; see locus 6 in [Table 1](#T1){ref-type="table"}). Cell adhesion molecule 2 (*CADM2*) belongs to the immunoglobulin superfamily and interacts with other cytoskeletal proteins ([@B10]). It is predominantly expressed in the central and peripheral nervous systems ([@B101]; [@B86]; [Supplementary Figure S3](#FS1){ref-type="supplementary-material"}) and regulates, e.g., synapse formation ([@B111]). Obesity risk variants ([@B145]; [@B86]) were associated with increased *CADM1* and *CADM2* expression in the hypothalamus with a complex interplay of *CADM1* and *CADM2* ([@B111]). Reduced expression promoted a negative energy balance and weight loss in mice ([@B111]). The expression of both *CADM1* and *CADM2* in several neuronal circuits suggests an intertwining of body weight maintenance with motor control, but also behavioral aspects, cognition, and memory ([@B111]). In addition to associations with obesity risk genes (SNP rs13078807 located in the second intron of *CADM2*) novel associations of *CADM2* genetic variants with systolic blood pressure (SBP), CRP levels ([@B86]), as well as with diverse psychological traits (neuroticism, mood instability, and risk-taking) have been detected. Interestingly, other loci identified by SNPs for BMI and/or body fat distribution in the current study are involved in the immune system, too ([Supplementary Table S8](#TS1){ref-type="supplementary-material"}): *ITIH4* ([@B90]; locus 5, 3p21.1; BP, schizophrenia), *SLC39A8* ([@B70]; locus 9, 4q24; schizophrenia, intelligence), and *HLA-DRB1* ([@B5]; locus 34, 6p21.32; schizophrenia).

5.  We for the first time report an association of *MC4R* (locus 32; [Table 1](#T1){ref-type="table"} and [Supplementary Table S4](#TS1){ref-type="supplementary-material"}) with neuroticism. *MC4R* is well known for its role in BMI/obesity ([@B48]). Evidence from animal models links the *MC4R* to eating behavior in stress-induced anxiety-like or depression-like behavior, anhedonia, and corticosterone secretion ([@B68]; [@B69]; [@B116]). *MC4R* appears to interact with the *SAPAP3* gene regulating compulsive behavior and body weight ([@B144]). A higher rate of anxiety and compulsiveness in patients with AN might be mediated by the *MC4R* ([@B144]). The *MC4R* (rs17782313-C) has also been associated with elevated scores for emotional eating and craving for food ([@B147]). Gain of function variants in *MC4R*, which have a weight lowering effect ([@B138]), have been associated with binge eating disorder (BED) in overweight subjects. Apart from polymorphisms exerting weak effects on BMI 166 *MC4R* mutations mostly entailing a loss in function have been identified up to date mainly in obese individuals ([@B48]). Apart from obesity, mutation carriers showed increased lean mass, increased linear growth, hyperphagia, hyperinsulinemia, and ADHD ([@B74]; [@B2]; [@B48]).

Limitations {#S5}
===========

Limitations of our study include: (i) we conducted a look-up analysis using summary statistics, so that we could not analyze covariates. (ii) The number of hits was higher for mental phenotypes with higher heritability, higher number of genome-wide significant loci, and/or higher numbers of subjects in the respective GWAS. Therefore, we suspect a type 2 error for phenotypes with a currently low number of identified loci. (iii) We had performed a Bonferroni correction for the 1,005 SNPs. As a drawback true associations may have been missed. On the other hand, we did not correct for the number of analyzed traits. (iv) We were unable to systematically consider the ancestry/ethnicity of the study groups comprising the diverse GWAS. However, as most data were derived from individuals of European descent this should represent a minor issue only. For those loci, which were detected in non-European study groups, we checked *P*-values and effect directions in recent GWAS conducted in individuals of European descent. (v) The progress in GWAS research leads to the release of many new analyses every year. For most phenotypes the selected GWAS data sets are the most recent ones; it was, however, not possible to include the most recent analyses, e.g., for WHR~adjBMI~ ([@B107]), BMI ([@B146]), and schizophrenia ([@B99]) in our look-up analyses. We were, however, able to use these most recent studies for MR-analysis and additional look-ups. (vi) Sex- and age-stratified analyses were not possible as the respective data sets were not available for all traits despite evidence for differences in genetic regulation for BMI and body fat distribution depending on age and sex ([@B133]; [@B142]; [@B107]; [@B110]). For body shape (WHR~adjBMI~), age effects were not found ([@B142]). (viii) It needs to be noted that across the literature for body fat distribution the term "adjusted for BMI" is not defined uniformly. It can either mean that the measurement (WC, HC, and WHR) is directly adjusted for BMI or that the estimation of the SNP effects in a GWAS was adjusted for BMI. For future GWAS a clear definition of the term "adjusted for BMI" is needed. (viii) We defined loci mainly via a central SNP and a surrounding region (±500 kb). However, some loci might actually represent more than one independent locus. We attempted to detect independent hits by analysis of linkage disequilibrium; nevertheless, independent SNPs within a given locus may have escaped detection. (ix) A clinically relevant aspect of the relationship between BMI and mental disorders is the susceptibility to weight gain as a side effect of treatment with especially atypical antipsychotic drugs. Because the GWAS data for the anthropometric traits are mostly based on "healthy" individuals, large scale confounding via use of psychotropic drugs *a priori* appears unlikely. (x) Study samples for some of the examined phenotypes are not completely independent. Sample overlap can potentially affect the results of cross-trait analysis. Since our analyses were conducted using summary statistics it is not possible to determine an exact number of overlapping participants between the underlying GWAS used in our analyses. To assess whether the overlap can be assumed, we looked at whether GWAS studies included in our analysis used data from the same study groups.

The GWAS study on body fat distribution ([@B107]), which we used for our MR analysis included a total of 29 study groups of the PGC and of UK Biobank. Four cohorts (B58C-WTCCC, TWINSUK, EGCUT, and KORA) are also mentioned as sources of controls for GWAS for schizophrenia ([@B99]), which we used as outcome phenotype. For cases with schizophrenia CLOZUK1, CLOZUK2, and CardiffCOGS cohorts and the PGC cohorts were used. These study groups were apparently not used for the GWAS on body fat distribution ([@B107]).

Two-sample MR assumes independent samples. Violation of this assumption will result in increased Type 1 error and biased effect estimates ([@B16]). For a continuous outcome, bias due to sample overlap is a linear function of the proportion of overlap between the samples with IVW method. Bias due to sample overlap may be more serious for the MR-Egger method. In a simulation analyses for binary outcome with sample overlap in the controls only -- as it is the case in our study -- there was no detectable bias in the IV estimates even with extremely weak instruments, nor was there any inflation of type 1 error rates ([@B16]). Accordingly, in our MR study, the sample overlap between controls of schizophrenia GWAS and study participants for GWAS on risk variable (i.e., WHR adjusted for BMI) do not lead to a bias for estimated causality in two sample MRs with binary outcome ([@B16]).

Sample overlap can also influence the results of the look-up analysis. As an example we compared studies that were included in the GWAS on BMI (158 studies in total; [@B72]) and studies that were included in the GWAS on educational attainment (63 studies in total; [@B97]). This comparison revealed that nineteen studies were the same.

We also checked the overlapping of the study groups included in the GWAS on BMI (GIANT; [@B72]) and in the GWAS on schizophrenia (PGC; [@B115]). It is possible that a certain number of controls for the GWAS on schizophrenia were the same individuals included in GWAS on BMI (overlapping cohorts were EGCUT, MIGen, WTCCC, KORA, HRN, MGS, and deCODE).

The sample overlap between the GWAS on psychiatric disorders due to comorbidity should also be considered. This topic had previously been investigated using data from PGC ([@B61]). They found that the overlap was less than 2% for eight psychiatric disorders. Data sets in the study were the same as in our study for four disorders (ADHD, AN, MDD, and schizophrenia). Nevertheless, we can probably assume that the sample overlap is of a similar magnitude for studies included in our analyses.

Conclusion {#S6}
==========

We identified several loci that were associated with BMI, body composition and/or body fat distribution, and mental disorders/traits. The SNPs for body composition and body fat distribution (WC, HC, WHR, BF%, and BFM) associated with mental disorders/traits were all simultaneously associated with BMI. Hence, an isolated effect of body fat distribution on mental phenotypes implied by clinical and epidemiological studies ([@B78]; [@B9]; [@B42]; [@B77]; [@B87]; [@B20]; [@B21]; [@B92]), was not substantiated. In the MR analysis, we did not detect a general causal effect of body fat distribution on schizophrenia. Our study has confirmed some known cross-phenotype associations ([@B13]) but has also given some new clues for genetic loci involved in both anthropometric traits and mental phenotypes.
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